Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Stagwell Inc. reported Q3 2026 revenue of $816 million, a 10% year-over-year increase, driven by significant growth in its Digital Transformation and Marketing Cloud segments. The company raised its full-year 2026 guidance for Adjusted EBITDA and Adjusted EPS following record net new business of $168 million in the quarter.
Term
Q3 2026
“This is the biggest quarter in Stagwell’s history. It shows we are on track to become number one in marketing transformation. Software products, like our agentic Stagwell Machines, and the Digital Transformation segment are driving our business as we pivot from primarily marketing services to AI-powe”
Kymera Therapeutics reported collaboration revenue of $99.4 million for the nine months ended September 30, 2026, a significant increase from $36.3 million in the prior year. Despite this, the company recorded a net loss of $262.4$ million for the period due to rising research and development expenses, which reached $346.2 million.
CCC Intelligent Solutions reported third quarter 2026 revenue of $294.1 million, a 10% increase year-over-year, driven by strong adoption of its AI-related solutions. The company also highlighted its pending $6.1 billion acquisition by a consortium led by GTCR and Elliott Investment Management, which is expected to close in Q1 2027. GAAP net income improved significantly to $30.2 million compared to a net loss in the prior year period.
“CCC delivered strong third quarter results, with revenue growth of 10% and adjusted EBITDA margin of approximately 44%. Our performance reflects the durability of our business, the trust customers place in us, and the increasing role our platform plays in helping participants across the insurance economy operate more efficiently and achieve better outcomes.”
Githesh Ramamurthy, Chairman & CEO of CCC
“The pending transaction with GTCR and Elliott marks an exciting next chapter for CCC and our customers. Together, we expect to accelerate the AI and agentic capabilities our customers want from us, expand the network at the center of our platform, and make long-term investments in innovation that help customers navigate growing complexity across the claims lifecycle.”
Ligand Pharmaceuticals reported Q3 2026 financial results, highlighted by a 51% year-over-year increase in royalty revenue to $70.3 million, driven by the XOMA portfolio and commercial momentum of Filspari. The company raised its full-year 2026 adjusted diluted EPS guidance to a range of $9.50 to $9.75 while reaffirming its total revenue guidance.
Term
Q3 2026
“Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari.”
Laureate Education reported Q3 2026 financial results with revenue increasing 21% to $485.1 million and net income rising to $101.2 million. The company reaffirmed its full-year 2026 guidance and announced a $150 million increase to its share repurchase authorization.
Term
Q3 2026
“We are pleased to report strong new enrollment intakes in both of our markets. The primary intake in Mexico included a very successful launch of our new campus in Puebla, as well as further growth in existing campuses. During the secondary intake in Peru, we continued to leverage our fully online capabilities to meet growing demand for working adults as that market scales.”
Eilif Serck-Hanssen, President and Chief Executive Officer
West Bancorporation reported Q3 2026 net income of $11.6 million, an increase from $9.3 million in the prior year period, driven by margin expansion and expense discipline. The company also declared a quarterly dividend of $0.26 per share and reported pristine credit quality with zero nonaccrual loans.
Term
Q3 2026
“Our net income for the first nine months of 2026 has increased 32 percent compared to the first nine months of 2025. Our annualized return on average equity has improved to 16.18 percent for the first nine months of 2026, compared to 14.27 percent for the first nine months of 2025 and our annualized return on average assets has grown to 1.16 percent in the third quarter of 2026.”
David Nelson, President and Chief Executive Officer
“Our balance sheet remains exceptionally strong, supported by solid capital and liquidity levels. Credit quality remains pristine with no loans on nonaccrual status at September 30, 2026. Additionally, this marks our ninth consecutive quarter-end with no loans greater than 30 days past due.”
David Nelson, President and Chief Executive Officer
Laureate Education reported strong growth for the third quarter of 2026, with revenues increasing to $485.1 million from $400.2 million in the prior year period. Net income attributable to the company rose significantly to $101.2 million, driven by improved operating performance and favorable foreign currency exchange gains.
Bicycle Therapeutics reported collaboration revenue of $34.1 million for the quarter ended September 30, 2026, a significant increase from $11.7 million in the prior year. The company reduced its quarterly net loss to $9.3 million compared to $58.9 million in 2025, primarily driven by higher revenue and a decrease in research and development expenses following a strategic reprioritization.
West Bancorporation reported net income of $33.3 million for the first nine months of 2026, a significant increase from $25.1 million in the same period of 2025, driven primarily by higher net interest income. Total assets decreased to $3.89 billion as of September 30, 2026, compared to $4.14 billion at year-end 2025, largely due to a reduction in interest-earning deposits with banks.
Garrett Motion Inc. reported net sales of $930 million for the third quarter of 2026, a 3.1% increase compared to $902 million in the prior year. Net income rose to $97 million from $77 million, driven by higher gross profit and lower tax expenses, while the company continued its share repurchase program, spending $172 million in the first nine months of the year.
Blue Owl Capital reported its third quarter 2026 financial results, highlighting nearly $50 billion raised over the last twelve months and total assets under management of $330 billion. The company also declared a quarterly cash dividend of $0.23 per Class A share, payable on November 23, 2026.
Term
Q3 2026
“Blue Owl demonstrated durability, resilience and an acceleration of growth during the third quarter. Our strategies continue to generate excellent investment results, and we believe the nearly $50 billion we’ve raised over the last twelve months reflects ongoing investor support and conviction around our disciplined approach to investing.”
Doug Ostrover and Marc Lipschultz, Co-CEOs of Blue Owl
Life Time Group Holdings reported strong growth for the nine months ended September 30, 2026, with total revenue increasing to $2.55 billion from $2.25 billion in the prior year. Net income rose to $295.9 million, supported by a significant increase in center revenue and improved operating margins, while the company continued heavy investment in capital expenditures totaling $812.0 million.
Linde plc reported record third-quarter 2026 sales of $9.4 billion, up 9% year-over-year, driven by price attainment and volume growth in electronics and chemicals. Adjusted EPS rose 9% to $4.59, and the company generated strong operating cash flow of $3.2 billion. Management narrowed its full-year 2026 adjusted EPS guidance to $17.82 - $17.92, representing 8% to 9% growth.
Term
Q3 2026
“Linde’s financial performance continued to improve in the third quarter, with record sales of $9.4 billion and record EPS of $4.59, alongside strong operating cash flow of $3.2 billion. During the quarter we took further actions to improve productivity and strengthen performance across our businesses, while maintaining our goal to deliver industry-leading results.”
Sanjiv Lamba, Chief Executive Officer
“Customer proposal activity remains robust, particularly across electronics, supporting our confidence in continued backlog growth. Regardless of the economic environment, we remain focused on operational excellence, disciplined capital deployment and securing high-quality projects that will compound shareholder value over the long term.”
Axalta Coating Systems reported Q3 2026 financial results with net sales of $1.3 billion, up 2% year-over-year, driven by record performance in its Mobility segment. Net income was $95 million, impacted by $14 million in merger and acquisition-related expenses, while the company achieved its lowest-ever total net leverage of 2.1x.
Term
3 months
“Axalta delivered another quarter of revenue growth, strong cash generation and robust profitability despite a more challenging operating environment. We maintained Adjusted EBITDA margin above 20%, further strengthened our balance sheet and achieved record quarterly net sales in Mobility Coatings. As we look ahead, we remain focused on disciplined execution and are confident in the significant value creation opportunity associated with our proposed combination with AkzoNobel.”
Chris Villavarayan, Chief Executive Officer and President of Axalta
Myers Industries reported net sales of $171.3 million for the quarter ended September 30, 2026, an increase from $158.5 million in the prior year. However, the company realized a net loss of $0.87 million for the quarter, primarily driven by a $5.6 million loss from discontinued operations and a $3.5 million loss on debt extinguishment.
Kymera Therapeutics reported financial results for the third quarter ended September 30, 2026, and announced positive Phase 1 data for its IRF5 degrader, KT-579. The company remains well-capitalized with $1.6 billion in cash, providing a runway into 2029, and expects topline Phase 2b data for its STAT6 degrader, KT-621, by year-end 2026.
Term
Q3 2026
“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology. With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape.”
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics
“The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways through a single oral mechanism.”
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics
Allegro MicroSystems reported Q2 fiscal 2027 revenue of $277 million, a 29% increase year-over-year, driven by record sales in Data Center and Industrial segments. GAAP diluted EPS quadrupled to $0.12, while non-GAAP EPS doubled to $0.26 compared to the prior year period.
Term
Q2 2027
“We saw continued strong momentum in our fiscal second quarter, delivering our seventh consecutive quarter of sequential sales growth. Sales were $277 million, representing a 29% increase year-over-year. GAAP earnings per share quadrupled from $0.03 per share in the fiscal second quarter of 2026 to $0.12. Non-GAAP EPS grew to $0.26, doubling over the second quarter of fiscal 2026.”
Mike Doogue, President and CEO
“During the quarter, we also continued to execute on our strategic priorities of expanding profitability and generating strong cash flow. On September 30, 2026, following the close of the second quarter, we made another $25 million voluntary debt repayment, underscoring the strength of our balance sheet and our confidence in Allegro’s anticipated free cash flow generation.”
HII reported record third-quarter revenues of $3.5 billion, a 10.8% increase year-over-year, driven by growth in its shipbuilding segments. The company secured $32.4 billion in new contract awards during the quarter, providing visibility for approximately 90% of expected shipbuilding revenue through 2030.
Term
Q3 2026
“Our third quarter results reflect solid performance across all three segments, and the significant awards we received during the quarter have now secured approximately 90 percent of our expected shipbuilding revenue through 2030. With that visibility, our focus is squarely on shipbuilding execution. At Mission Technologies, we won landmark maritime autonomy awards for the Medium Unmanned Surface Vessel (MUSV) and the Lionfish Small Unmanned Undersea Vehicle (SUUV), demonstrating our continued leadership in unmanned systems and maritime autonomy.”
Altria reported Q3 2026 financial results with net revenues of $6.13 billion and adjusted diluted EPS growth of 4.8%. The company also announced a $1 billion expansion of its share repurchase program and raised its full-year 2026 adjusted EPS guidance.
“Altria delivered strong financial performance in the third quarter, growing adjusted diluted earnings per share by 4.8%, while continuing to invest in our Vision and building on our foundation for the future.”
Sal Mancuso, Altria’s Chief Executive Officer
“Our strong performance through the first nine months and confidence in our full-year plan allowed us to raise our earnings guidance for the year. We now expect to deliver adjusted diluted EPS in a range of $5.66 to $5.74, representing a growth rate of 4.5% to 6.0% from a base of $5.42 in 2025.”
Criteo S.A. appointed Jianchang "JC" Mao, a former Google and Microsoft technology executive, to its Board of Directors effective October 28, 2026. He succeeds Edmond Mesrobian, who resigned from the Board and its Compensation Committee after nearly a decade of service. Mr. Mao will receive compensation in accordance with the company's standard independent director program.
Bridgewater Bancshares reported net income available to common shareholders of $14.0 million for the quarter ended September 30, 2026, up from $10.6 million in the prior year period. The increase was driven by higher net interest income and a significant gain on the sale of available-for-sale securities during the nine-month period.
West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million, an 8.7% increase driven by strong organic growth in its High-Value Product (HVP) Components business. Due to the strong performance, the company raised its full-year 2026 net sales guidance to a range of $3.41 billion to $3.42 billion and its adjusted-diluted EPS guidance to $9.38 to $9.48.
Term
Q3 2026
“I am pleased to report strong third-quarter 2026 results, with net sales and adjusted EPS exceeding our expectations. Our results were again led by our High-Value Product (HVP) Components business. The robust sales performance drove strong operating income margin expansion and EPS growth. As a result of our team's strong execution in the third quarter, we are increasing our full-year 2026 guidance.”
Michel Lagarde, President and Chief Executive Officer
“I want to thank our global teams for their relentless focus on execution to deliver products and services for our customers and the patients they serve. West is a critical primary containment and drug delivery partner for pharmaceutical companies, biotechs and CDMOs around the world. We are grateful for the trust our customers put in us, and we remain committed to driving continuous improvement to even better serve their current and future needs.”
Michel Lagarde, President and Chief Executive Officer
Bristol Myers Squibb reported third quarter 2026 revenues of $13.1 billion, a 7% increase driven by double-digit growth in its Growth Portfolio. The company raised its full-year 2026 revenue guidance to a range of $49.75 billion to $50.25 billion following strong performance from key products like Opdivo Qvantig and Reblozyl.
Term
Q3 2026
“We delivered another quarter of double-digit growth in our Growth Portfolio, which increased 12% and reflects the continued momentum across our diversified portfolio. The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones. As we look forward to additional late-stage data in the near term, we remain focused on executing with discipline, investing where we see the greatest opportunity and strengthening the foundation for sustainable growth.”
Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb
T. Rowe Price Group reported third quarter 2026 net revenues of $2.0 billion and diluted EPS of $2.79. Assets under management (AUM) ended the period at $1.86 trillion, despite net client outflows of $28.3 billion during the quarter.
“We continue to expand our ETF, SMA, and model portfolio businesses, extending our active investment expertise to more clients through a broader range of portfolio solutions. With innovative product launches, improving investment performance, and continued progress on our strategic partnerships, we are well positioned to continue delivering long-term value for clients and stockholders.”
Bicycle Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $469.9 million and a runway extending into 2030. The company also announced that the FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer and plans to initiate its first company-sponsored radioligand clinical trial in 2H 2027.
“We are pleased with the continued progress made across our pipeline during the third quarter, as we advance nuzefatide pevedotin in the Phase 2 clinical trial in patients with recurrent pancreatic ductal adenocarcinoma and build our emerging pipeline of next-generation radioligands.”
Kevin Lee, Ph.D., Bicycle CEO
“We remain focused on disciplined execution across our prioritized programs and believe our growing clinical data continue to demonstrate the potential of Bicycle® molecules to deliver highly targeted therapies with differentiated benefit/risk profiles.”
Life Time Group Holdings reported third quarter 2026 financial results with total revenue increasing 14.2% to $893.5 million and net income rising 4.0% to $106.5 million. The company raised its full-year 2026 outlook and remains on track to open 14 new clubs this year with a robust pipeline for 2027.
Term
Q3 2026
“Our third quarter results reflect our continued delivery of exceptional member experiences and the strength of our brand. Member engagement continues to rise and our in-center businesses are performing very well, resulting in higher revenue per membership. We are on track to open all 14 new clubs planned for this year, and nearly all of our clubs planned for 2027 are already under construction. With our low leverage, strong cash flow and robust real estate pipeline, we are well positioned for long-term growth.”
The Clorox Company appointed Fabian Garcia as CEO and a member of the Board, effective January 5, 2027, succeeding Linda Rendle. Mr. Garcia's compensation package includes a $100,000 base salary, a $2 million target annual bonus, and a $11 million one-time sign-on RSU award to compensate for forfeited equity from his previous employer.
Howmet Aerospace reported record Q3 2026 revenue growth of 29% year-over-year to $2.7 billion, driven by robust commercial aerospace demand. The company's Board authorized a significant $5 billion increase to its share repurchase program and raised full-year 2026 guidance.
Term
Q3 2026
“Howmet's performance was solid in all dimensions, with third quarter results exceeding the high end of guidance. Revenue grew 29% year over year and 25% organically, the strongest quarterly growth rate on record for Howmet.”
John Plant, Executive Chairman and Chief Executive Officer
“Our trajectory points to a healthy fourth quarter and the conclusion of another strong year for Howmet. The commercial aerospace market continues to look robust, underpinned by the extraordinary aircraft order backlog that supports expected production volume increases throughout 2027 and beyond.”
John Plant, Executive Chairman and Chief Executive Officer
Phathom Pharmaceuticals reported a significant increase in net product revenue to $84.7 million for Q3 2026, up from $49.5 million in the prior year. The company substantially narrowed its quarterly net loss to $13.9 million compared to $30.0 million in Q3 2025, driven by higher gross profits and reduced operating expenses.
Myers Industries reported Q3 2026 revenue growth of 8.1% to $171.3 million, driven by strong performance in the Infrastructure and Food & Beverage end markets. However, margins were pressured by a significant spike in resin costs and unfavorable product mix, leading to a decrease in operating income. The company completed the divestiture of Myers Tire Supply during the period to focus on its core specialty engineered products growth platforms.
Term
Q3 2026
“Our Focused Transformation initiatives continued to drive commercial excellence across our growth platforms, resulting in a year-over-year increase in revenue. At the same time, a significant spike in resin cost and unfavorable product mix pressured gross margins in the quarter. Resin costs have since declined and stabilized from their recent peak, while our pricing actions remain in place and continue to support margin recovery.”